Abstract:Background Liver X receptor (LXR) belongs to the metabolic nuclear receptor superfamily, which plays a critical regulatory role in vascular physiology/pathology. However, effects of systemic LXR activation on established vulnerable plaques and the potential isotype‐specific role involved remain unclear. Methods and Results The 8‐week‐old male apolipoprotein E−/− mice went through carotid branch ligation and renal artery constriction, combined with a high‐fat diet. Plaques in the left carotid artery acquired vulnerable features 4 weeks later, confirmed by magnetic resonance imaging scans and histological analysis. From that time on, mice were injected intraperitoneally daily with PBS or GW3965 (10 mg/kg per day) for an additional 4 weeks. Treatment with LXR agonists reduced the lesion volume by 52.61%, compared with the vehicle group. More important, a profile of less intraplaque hemorrhage detection and necrotic core formation was found. These actions collectively attenuated the incidence of plaque rupture. Mechanistically, reduced lesional apoptosis, enhanced efferocytosis, and alleviated endoplasmic reticulum stress are involved in the process. Furthermore, genetic ablation of LXRα, but not LXRβ, blunted the protective effects of LXR on the endoplasmic reticulum stress–elicited C/EBP‐homologous protein pathway in peritoneal macrophages. In concert with the LXRα‐predominant role in vitro, activated LXR failed to stabilize vulnerable plaques and correct the acquired cellular anomalies in LXRα−/− apolipoprotein E−/− mice. Conclusions Our results revealed that LXRα mediates the capacity of LXR activation to stabilize vulnerable plaques and prevent plaque rupture via amelioration of macrophage endoplasmic reticulum stress, lesional apoptosis, and defective efferocytosis. These findings might expand the application scenarios of LXR therapeutics for atherosclerosis.

LXR agonists: new potential therapeutic drug for neurodegenerative diseases

LXR agonism for CNS diseases: promises and challenges

Liver X receptors as potential therapeutic targets for multiple diseases.

Liver X receptors：the new orientation of drugs for metabolic diseases

Lipid Metabolism and Neuroinflammation in Alzheimer's Disease: A Role for Liver X Receptors

Liver X Receptor Activation Attenuates Inflammatory Response and Protects Cholinergic Neurons in App/Ps1 Transgenic Mice

New Drug Targets LXR for Cholesterol Control

Activation of Liver X Receptor Β-Enhancing Neurogenesis Ameliorates Cognitive Impairment Induced by Chronic Cerebral Hypoperfusion.

Liver X Receptors And Their Agonists: Targeting For Cholesterol Homeostasis And Cardiovascular Diseases

Liver X Receptors As Potential Therapeutic Targets in Atherosclerosis

Identification of Side Chain Oxidized Sterols As Novel Liver X Receptor Agonists with Therapeutic Potential in the Treatment of Cardiovascular and Neurodegenerative Diseases

Liver X receptor: a potential target in the treatment of atherosclerosis

Discovery of Tissue Selective Liver X Receptor Agonists for the Treatment of Atherosclerosis Without Causing Hepatic Lipogenesis.

Research progress on antiatherosclerosis mechanism of liver X receptors

Targeting Liver X Receptors for the Treatment of Non-Alcoholic Fatty Liver Disease

Recent Advances on Liver X Receptors

Lipoxins in the Nervous System: Brighter Prospects for Neuroprotection

Liver X receptors bridge hepatic lipid metabolism and inflammation.

Protective Functions of Liver X Receptor Α in Established Vulnerable Plaques: Involvement of Regulating Endoplasmic Reticulum–Mediated Macrophage Apoptosis and Efferocytosis

Synthesis of liver X receptor agonists from hydeoxycholic acid

Liver X receptors conserve the therapeutic target potential for the treatment of rheumatoid arthritis